Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.
Market Cap | 492.153 Million | Shares Outstanding | 121.82 Million | Avg 30-day Volume | 1.006 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.2 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -138.231 Million |
Price to Book Value | 2.5792 | Operating Margin | 0.0 | Enterprise Value | 576.73 Million |
Current Ratio | 13.214 | EPS Growth | 0 | Quick Ratio | 12.859 |
1 Yr BETA | 1.3483 | 52-week High/Low | 12.8 / 3.6 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -41.5322 | Altman Z-Score | 5.7588 | Free Cash Flow to Firm | 0 |
Earnings Report | 2023-03-23 |
Please sign in first
765.4 Thousand total shares from 7 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
LIM JONATHAN E CHAIRMAN & CEO |
|
32,155,582 | 2023-01-10 | 3 |
|
12,000 | 2022-12-21 | 2 | |
|
207,500 | 2022-12-21 | 2 | |
CORMORANT ASSET MANAGEMENT, LP |
|
11,019,912 | 2022-12-20 | 2 |
|
537,724 | 2022-12-15 | 3 | |
|
40,000 | 2022-06-22 | 1 | |
|
40,000 | 2022-06-22 | 1 | |
|
10,712,220 | 2022-06-22 | 1 | |
|
60,000 | 2022-06-22 | 1 | |
|
0 | 2022-04-25 | 2 | |
GARNER EBUN GENERAL COUNSEL & CORP. SEC. |
|
173,000 | 2022-02-01 | 1 |
CHACKO DAVID M. CHIEF FINANCIAL OFFICER |
|
603,623 | 2022-02-01 | 1 |
WEI LIN CHIEF MEDICAL OFFICER |
|
586,162 | 2022-02-01 | 1 |
ARCH VENTURE FUND X OVERAGE, L.P. |
|
11,055,554 | 2021-07-20 | 0 |
LIM JONATHAN E SEE REMARKS |
|
32,055,582 | 2021-07-20 | 3 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LIM JONATHAN E - Director - Officer - > 10% Owner CHAIRMAN & CEO by jonathan e. lim and conyee t. lim family trust, dated april 28, 2005 |
2023-01-10 16:46:07 -0500 | 2023-01-10 | P | 60,000 | $3.86 | a | 20,256,222 | indirect | 5.679 | -5.9259 | 5.679 | 2 | -5.9259 | 6 | ||
BRISTOL JAMES ARTHUR - Director by bristol survivor?s trust, dated october 26, 2019 |
2022-12-22 21:26:16 -0500 | 2022-12-21 | P | 20,000 | $4.14 | a | 20,000 | indirect | -5.122 | 3.9024 | 5.122 | 5 | -5.122 | 2 | ||
START VALERIE DENISE HARDING - Director by start 2006 trust |
2022-12-22 21:28:43 -0500 | 2022-12-21 | P | 10,000 | $4.64 | a | 10,000 | indirect | -5.122 | 3.9024 | 5.122 | 5 | -5.122 | 2 | ||
2022-12-15 16:47:21 -0500 | 2022-12-15 | P | 20,000 | $4.87 | a | 443,974 | direct | -2.1978 | -9.8901 | 0.0 | 1 | -9.8901 | 6 | |||
LIM JONATHAN E - Director - Officer - > 10% Owner CHAIRMAN & CEO by jonathan e. lim and conyee t. lim family trust, dated april 28, 2005 |
2022-12-15 11:53:55 -0500 | 2022-12-14 | P | 40,000 | $4.99 | a | 20,196,222 | indirect | -4.6122 | -12.1593 | 0.0 | 1 | -12.1593 | 6 | ||
CHEN BIHUA - Director see footnotes CORMORANT ASSET MANAGEMENT, LP - Director see footnotes CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP - Director see footnotes CORMORANT PRIVATE HEALTHCARE FUND II, LP - Director see footnotes |
2022-12-20 17:42:47 -0500 | 2022-12-13 | P | 307,692 | $6.50 | a | 10,813,246 | indirect | -0.2381 | -1.9048 | 0.0 | 1 | -7.381 | 4 | ||
CHEN BIHUA - Director see footnotes CORMORANT ASSET MANAGEMENT, LP - Director see footnotes CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP - Director see footnotes CORMORANT PRIVATE HEALTHCARE FUND II, LP - Director see footnotes |
2022-12-21 16:33:57 -0500 | 2022-12-13 | P | 307,692 | $6.50 | a | 10,813,246 | indirect | -2.148 | 2.864 | 2.864 | 6 | -7.1599 | 3 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ERASCA INC ERAS | 2023-01-27 22:15:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 21:45:04 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 21:15:04 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 20:45:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 20:15:04 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 19:45:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 19:15:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 18:45:04 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 18:15:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 17:45:03 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 17:15:04 UTC | 3.6056 | 0.7144 | 300000 |
ERASCA INC ERAS | 2023-01-27 16:45:03 UTC | 3.6122 | 0.7078 | 300000 |
ERASCA INC ERAS | 2023-01-27 16:15:03 UTC | 3.6122 | 0.7078 | 300000 |
ERASCA INC ERAS | 2023-01-27 15:45:03 UTC | 3.6122 | 0.7078 | 350000 |
ERASCA INC ERAS | 2023-01-27 15:15:04 UTC | 3.6122 | 0.7078 | 350000 |
ERASCA INC ERAS | 2023-01-27 14:45:04 UTC | 3.5845 | 0.7355 | 300000 |
ERASCA INC ERAS | 2023-01-27 14:15:03 UTC | 3.5845 | 0.7355 | 350000 |
ERASCA INC ERAS | 2023-01-27 13:45:03 UTC | 3.6016 | 0.7184 | 350000 |
ERASCA INC ERAS | 2023-01-27 13:15:03 UTC | 3.6016 | 0.7184 | 300000 |
ERASCA INC ERAS | 2023-01-27 12:45:03 UTC | 3.6016 | 0.7184 | 300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ERAS | -1800.0 shares, $-14040.0 | 2022-09-30 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | ERAS | -20828.0 shares, $-162458.4 | 2022-09-30 | N-PORT |
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | ERAS | -1912.0 shares, $-15621.04 | 2022-10-31 | N-PORT |